Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
Both dose-dependent and idiosyncratic reactions have been documented
The prevalence of NAFLD has increased rapidly over the last two decades, in parallel with the dramatic rise in obesity and diabetes
Related resources: PT-141 Profile Melanotan II Dosage Protocol What it does: Melanotan II produces a deep tan without UV exposure (or with minimal sun)
Why Working with a Medical Expert Matters When it comes to something as precise as peptide therapy, a one-size-fits-all approach just doesnt work
US$ 22.61
US$ 28.43
US$ 25.65
US$ 28.21
US$ 29.75
